Furthermore, multiple reports indicate the key roles of TAF1(2) in AML and provide a new theoretical structural framework to develop direct-acting small molecule inhibitors of TAF1(2) as prospective inflammation pathophysiology and cancer therapeutics [16,17,18,19,20]. Here, TAF1 is linked to acute myeloid leukemia.